Abuse-Deterrent Testimony: Hamburg Defends Opioid Policy On The Hill
This article was originally published in The Pink Sheet Daily
“It doesn’t do any good to label something as abuse-deterrent if it actually isn’t,” the FDA Commissioner tells senators. “And right now, unfortunately, the technology is poor.”
You may also be interested in...
Opioid issues delayed Robert Califf’s confirmation as FDA commissioner. Could they prevent the nomination of Janet Woodcock?
FDA is only mentioned once in the document, and its temporary leadership may not be the reason why.
Pink Sheet reporters and editor discuss the influence of the emergency use authorization on FDA decisions, another twist in the march-in rights debate, and how CBER is not using the real-time oncology review program.